低危和中危前列腺癌立体定向体部放疗的多中心试验:生存和毒性终点
21个中心纳入309例前列腺腺癌患者(低危172例、中危137例),采用非共面机器人立体定向体部放疗平台实时追踪植入基准标记,处方剂量40 Gy分5次每次8 Gy。中位随访61个月,3级泌尿生殖毒性低危组1.2%、中危组1.5%,无4级或5级毒性;全组5年总生存率95.6%、无病生存率97.1%,低危组5年无病生存率97.3%优于历史对照的93%(P = .0008)。
要点
- 低危和中危前列腺癌患者接受40 Gy分5次SBRT,3级泌尿生殖毒性发生率低危组1.2%、中危组1.5%。
- 全组5年总生存率95.6%,无病生存率97.1%;低危组5年无病生存率97.3%,优于历史对照93%(P = .0008)。
- 未发生4级或5级毒性;所有3级毒性均为泌尿生殖毒性,发生于治疗后11至51个月。
核心结论
- 剂量递增前列腺SBRT在这项多中心研究中毒性极小,复发率与历史对照相比更优,SBRT是低危和中危前列腺癌的合适选择。
研究设计与样本
- 多中心试验纳入21个中心的309例前列腺腺癌患者,其中低危172例、中危137例。
- 所有患者接受非共面机器人SBRT平台治疗,实时追踪植入基准标记,前列腺处方剂量40 Gy分5次每次8 Gy。
- 毒性采用不良事件通用术语标准(CTCAE)第3版评估,生化失败采用「最低点+2」定义。
- 研究把握度:90%把握度识别过高的(>10%)≥3级泌尿生殖或胃肠道毒性发生率;低危组80%把握度显示无病生存优于93%的历史对照率。
主要发现
- 中位随访61个月,低危组2例(1.2%)和中危组2例(1.5%)发生3级泌尿生殖毒性,远低于被认为过高的10%毒性率(95%置信区间上限分别为3.5%和4.3%)。
- 未发生4级或5级毒性;所有3级毒性均为泌尿生殖毒性,发生于治疗后11至51个月。
- 全组5年实际总生存率为95.6%,无病生存率为97.1%。
- 低危组5年无病生存率为97.3%,优于历史对照的93%(P = .0008;95%置信区间下限为94.6%);中危组5年无病生存率为97.1%。
关键数值与推荐
- 前列腺处方剂量为40 Gy分5次,每次8 Gy。
- 生化失败采用「最低点+2」定义。
- 毒性分级采用CTCAE第3版。
- 低危组5年无病生存率97.3%优于历史对照93%(P = .0008;95%置信区间下限94.6%)。
临床怎么用
- 作者结论认为SBRT是低危和中危前列腺癌的合适选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The radiobiology of prostate cancer may favor the extreme hypofractionation inherent in stereotactic body radiation therapy (SBRT); however, data from a large multicenter study are lacking. We therefore examined the hypothesis that dose-escalated SBRT can be safely administered across multiple institutions, with favorable 5-year disease-free survival (DFS) rates compared with historical controls. METHODS AND MATERIALS: Twenty-one centers enrolled 309 patients with prostate adenocarcinoma: 172 with low-risk (LR) and 137 with intermediate-risk (IR) disease. All were treated with a non-coplanar robotic SBRT platform using real-time tracking of implanted fiducials. The prostate was prescribed 40 Gy in 5 fractions of 8 Gy. We assessed toxicities using Common Terminology Criteria for Adverse Events (CTCAE) version 3 and biochemical failure using the "nadir + 2" definition. The study population yielded 90% power to identify excessive (>10%) rates of grade ≥3 genitourinary (GU) or gastrointestinal toxicities and, in the LR group, 80% power to show superiority in DFS over a 93% historical comparison rate. RESULTS: At a median follow-up of 61 months, 2 LR patients (1.2%) and 2 IR patients (1.5%) experienced grade 3 GU toxicities, far below the 10% toxicity rate deemed excessive (upper limits of 95% confidence interval, 3.5% and 4.3%, respectively). No grade 4 or 5 toxicities occurred. All grade 3 toxicities were GU, occurring 11 to 51 months after treatment. For the entire group, the actuarial 5-year overall survival rate was 95.6% and the DFS rate was 97.1%. The 5-year DFS rate was 97.3% for LR patients (superior to the 93% DFS rate for historical controls; P = .0008; lower limit of 95% confidence interval, 94.6%) and 97.1% for IR patients. CONCLUSIONS: Dose-escalated prostate SBRT was administered with minimal toxicity in this multi-institutional study. Relapse rates compared favorably with historical controls. SBRT is a suitable option for LR and IR prostate cancer.
引用
- Meier RM, Bloch DA, Cotrutz C, et al. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. Int J Radiat Oncol Biol Phys. 2018. PMID: 30191864. doi:10.1016/j.ijrobp.2018.05.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。